Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients

NCT02938299 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT02938299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02938299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients
Lead sponsor
Philogen S.p.A.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 1, 2016
Completion date
December 31, 2028
Enrollment
214 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma